Incretin Effect on the Immunological Phenotype

NCT01782261 · Completed

Last updated 2026-05-28

This clinical trial tests how incretin affects immune cells in people with type 1 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 15 people

Who can join Ages 18–50 · all sexes Healthy volunteers accepted.

Timeline Started 2012-02 · est. completion 2015-02

Where 1 site · Austria

What this study is testing ClinicalTrials.gov NCT01782261 ↗

Description as written by the study sponsor.

Assessment of the effect of incretin based therapies (Liraglutide and Saxagliptin) on immune cells in healthy subjects and patients with type 1 diabetes

Treatments tested

Liraglutide also known as Victoza Drug

once daily subcutaneous injection
Saxagliptin also known as Onglyza Drug

once daily tablet

Main thing measured	Increase of regulatory FOXP3+ T cells
Sponsor	Medical University of Graz
Conditions studied	Type 1 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01782261 ↗